PharmaCyte Biotech (PMCB) amends Form 4 to cancel option grant

Rhea-AI Filing Summary

SCHECHTER JONATHAN reported acquisition or exercise transactions in this Form 4 filing.

PharmaCyte Biotech director Jonathan Schechter filed an amended insider report for a stock option (right to buy) entry dated March 31, 2026. A footnote explains that the reported grant was made in error and has been cancelled, leaving 0 options from this grant outstanding.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SCHECHTER JONATHAN

Role Director

Type	Security	Shares	Price	Value
Other	Stock Option (Right to Buy)	0	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Transaction date: 2026-03-31 Options in transaction: 0.0000 Options after transaction: 0.0000 +1 more

4 metrics

Transaction date 2026-03-31 Date of reported stock option (right to buy) transaction

Options in transaction 0.0000 Stock Option (Right to Buy) shares reported in the Form 4/A entry

Options after transaction 0.0000 Total stock options from this grant following the correction

Derivative transactions reported 1 Number of derivative-type transactions included in this amendment

Key Terms

Stock Option (Right to Buy), Other acquisition or disposition, Form 4/A, restructuring

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Other acquisition or disposition financial

"transaction_code_description: Other acquisition or disposition"

Form 4/A regulatory

"Form type: 4/A (amended insider transaction report)"

Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.

restructuring financial

"restructuringCount indicates 1 restructuring-style transaction"

Restructuring is a deliberate rearrangement of a company’s operations, finances, or ownership—like reorganizing a cluttered house to run more efficiently—often involving cost cuts, asset sales, debt changes, or staff moves. Investors pay attention because restructuring can improve profitability and free up cash, but it can also signal distress, incur one-time costs, or dilute shareholder value; its success affects future earnings and stock performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/17/2026 - 05:00 PM Accepted by SEC EDGAR 07/17/2026 - 05:00 PM Learn about SEC filing dates

FAQ

What does PharmaCyte Biotech (PMCB) disclose in Jonathan Schechter’s latest Form 4/A?

The amendment records a corrective entry for a stock option grant dated March 31, 2026. A footnote states the reported grant was made in error and has been cancelled, so no options from this grant remain outstanding after the adjustment.

Did Jonathan Schechter acquire any PharmaCyte Biotech (PMCB) options or shares in this Form 4/A?

No options or shares were effectively acquired in this filing. The transaction shows 0.0000 options and 0.0000 options held afterward, reflecting that the erroneously reported grant was cancelled rather than representing a new or retained economic position.

How many PharmaCyte Biotech (PMCB) options are reported after the corrected grant?

The amended report lists 0.0000 stock options following the transaction. This figure indicates that, after cancelling the mistaken grant identified in the footnote, there are no remaining options associated with this specific grant on Schechter’s reported holdings.

Was the PharmaCyte Biotech (PMCB) Form 4/A transaction under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked, so the corrective transaction is not reported as made under a Rule 10b5-1 trading plan. It is presented simply as an amendment cancelling a previously reported, erroneous option grant.

What transaction code and description are used in PharmaCyte Biotech’s (PMCB) Form 4/A for this option grant?

The entry is coded as transaction type J with an “Other acquisition or disposition” description for a derivative security. This reflects a restructuring-style correction, where the erroneous option grant is cancelled rather than a standard market purchase or sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHECHTER JONATHAN

(Last) (First) (Middle)

C/O PHARMACYTE BIOTECH, INC.

3960 HOWARD HUGHES PARKWAY, SUITE 500

(Street)

LAS VEGAS NEVADA 89169

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PharmaCyte Biotech, Inc. [ PMCB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/02/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)(1)	(1)	03/31/2026(1)		J(1)		0(1)		(1)	(1)	Common Stock(1)	(1)	(1)	0(1)	D

Explanation of Responses:

1. The reported grant was made in error and has been cancelled.

	/s/ Jonathan Schechter	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)